The EORTC's AML-13 trial evaluates the efficacy of rHuG-CSF in combination with chemotherapy for elderly patients with acute myeloid leukemia (AML). Given the aging population and the increasing incidence of AML, this study addresses a significant unmet medical need. The results could position rHuG-CSF as a critical adjunct therapy in AML treatment regimens, potentially enhancing market share for the sponsor and collaborators. The competitive landscape includes other G-CSF formulations and alternative therapies, necessitating a thorough analysis of clinical outcomes and market positioning. Diligence should focus on the trial's results and subsequent regulatory pathways for commercialization.